Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The combination of relatlimab/nivolumab and ipilimumab/nivolumab exhibited comparable effectiveness for progression-free survival (PFS) with a hazard ratio of 0.99 (95% confidence interval (CI) 0.75-1.31) and for overall response rate (RR) with a relative risk of 0.99 (95% CI 0.78-1.27).
• For patients with BRAF-mutant melanoma, the PD-(L)1/BRAF/MEK inhibitors triplet combination demonstrated superior PFS (hazard ratio (HR) = 0.56, 95% CI 0.37-0.84) and overall respose rate (ORR) (relative risk (RR) = 3.07, 95% CI 1.61-5.85) compared to ipilimumab/nivolumab.
• Nivolumab/relatlimab was suggested as a treatment for patients with unresectable or metastatic cutaneous melanoma, regardless of BRAF mutation status, broadening its applicability to a wider patient population.
• The combination of relatlimab/nivolumab was associated with a lower risk of grade ≥3 treatment-related adverse events (TRAEs) compared to ipilimumab/nivolumab (RR = 0.71, 95% CI 0.30-1.67), though the risk was still higher than monotherapy.
• Relatlimab/nivolumab had a lower but still notable risk of severe dermatologic immune-related adverse events (irAEs) compared to ipilimumab/nivolumab, which was associated with the highest toxicity for grade ≥3 TRAEs.
• There is no population types or subgroups information available in the reviewed documents.